The concern is why is stock down since UBS upgrade. That is not a good sign. Maybe INSMED started the $100 million financing program and the involved parties are currently sohrting them to buy them back cheaper from company to raise up to $100 million.
If that is the case then INSMED is smart. Pull that $100 million right before Russell inclusion is a smart thing to do. Less dilution. Not worth to take the risk and hopethat the clinical news will always be good and stock may trade higher than $13 in coming months.
If you are client of UBS then you will see it. Or if you have access to some paying services then you will see it. Company will never release a news, and some other 3rd firms may or may not mentione the artcile. Some smallers firms are cheaper and easier to get an access than bigger firms like UBS.
I was able to buy some from firms coverage for $25, but like I said not all brokers sell their services to non-members.